South African healthcare workers' knowledge of dolutegravir's drug-drug interactions in the first year of its rollout: a cross-sectional online survey.
antiretroviral agents
drug interactions
health personnel
knowledge
practice guideline
training
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
05
08
2021
accepted:
19
01
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
11
3
2022
Statut:
ppublish
Résumé
In December 2019, dolutegravir-based treatment was recommended as first-line antiretroviral therapy (ART) in South Africa. Dolutegravir has clinically significant interactions with several commonly used drugs, such as rifampicin, metformin and cation-containing medicines. National guidelines detail these interactions and how to manage them. While previous international studies have shown low healthcare worker knowledge of drug-drug interactions, there is a paucity of information on antiretroviral interaction knowledge in the South African setting, where much ART is nurse-led. The study aimed to determine this knowledge and to describe which variables were associated with gaps in knowledge. An anonymous online survey of healthcare workers in the field of HIV was conducted in August/September 2020. The survey was designed, tested and piloted, and included sections on demographics, guideline access and training, interaction knowledge, counselling and the effect of COVID-19. Dissemination was via e-mail and social media (convenience sampling). Descriptive and inferential analysis was done using proportions and the 95% confidence interval to determine relationships between independent and dependent variables. Research ethics approval was obtained from the University of Cape Town's Human Research Ethics Committee (HREC Ref: 357/2020). In total, 1950 survey responses were included in the analysis - 47.1% nurses, 35.8% doctors and 8.9% pharmacists. When asked whether they were aware that dolutegravir has interactions, 70% said yes, 13.9% said no and 16.1% did not answer. Knowledge of specific interactions and the dosing changes needed was low with a wide range between different drugs: 79.7% knew to double the dolutegravir dose with rifampicin, but with calcium, 5.1% picked both correct dosing options and 33.7% picked one of the two correct options. Access to guidelines and training were positively associated with drug interaction knowledge. There are gaps in the awareness and knowledge of dolutegravir interactions and how to adjust dosing among South African healthcare workers.
Identifiants
pubmed: 35255196
doi: 10.1002/jia2.25885
pmc: PMC8901146
doi:
Substances chimiques
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25885Informations de copyright
© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
J Int AIDS Soc. 2009 Feb 02;12:1
pubmed: 19183506
Int J Antimicrob Agents. 2019 Aug;54(2):202-206
pubmed: 31002950
Front Med (Lausanne). 2021 Mar 01;8:650369
pubmed: 33732726
AIDS Rev. 2015 Jan-Mar;17(1):56-64
pubmed: 25472016
Clin Infect Dis. 2020 Feb 3;70(4):549-556
pubmed: 30918967
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):400-7
pubmed: 26974526
Curr Obstet Gynecol Rep. 2020 Sep;9(3):98-104
pubmed: 33552676
J Antimicrob Chemother. 2011 Jul;66(7):1567-72
pubmed: 21493648
J Acquir Immune Defic Syndr. 2017 May 1;75(1):e24-e26
pubmed: 28114188
Eur J Clin Pharmacol. 2016 Jun;72(6):665-70
pubmed: 26898568
Clin Pharmacokinet. 2013 Nov;52(11):981-94
pubmed: 23824675
South Afr J HIV Med. 2018 Apr 12;19(1):778
pubmed: 29707389
HIV Med. 2020 Jan;21(1):53-63
pubmed: 31532898
Saudi Pharm J. 2019 May;27(4):463-466
pubmed: 31061613
J Antimicrob Chemother. 2015 Dec;70(12):3317-22
pubmed: 26286575
J Clin Pharmacol. 2015 May;55(5):490-6
pubmed: 25449994
South Afr J HIV Med. 2021 Mar 11;22(1):1196
pubmed: 33824736
J Popul Ther Clin Pharmacol. 2019 Jan 22;26(1):e1-e19
pubmed: 31002484
AIDS. 2018 Feb 20;32(4):532-533
pubmed: 29381562
EClinicalMedicine. 2020 Oct 16;28:100573
pubmed: 33294805
Ther Drug Monit. 2020 Apr;42(2):330-334
pubmed: 31743292
J Antimicrob Chemother. 2016 Jun;71(6):1632-6
pubmed: 26888910
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):111-115
pubmed: 31335593
BMC Health Serv Res. 2018 Dec 14;18(1):965
pubmed: 30547793
Clin Infect Dis. 2010 May 15;50(10):1419-21
pubmed: 20380564
J Infect Chemother. 2018 Jun;24(6):476-478
pubmed: 29415844
BMJ Case Rep. 2021 Jan 6;14(1):
pubmed: 33408101
J Clin Med. 2018 Aug 22;7(9):
pubmed: 30135390
Ann Pharmacother. 2015 Jul;49(7):784-9
pubmed: 25862012
AIDS. 2017 Sep 24;31(15):2176-2177
pubmed: 28906282
Am J Obstet Gynecol. 2016 Mar;214(3):385.e1-7
pubmed: 26928154